Do analysts believe Bio-Key Intl (NASDAQ:BKYI) will continue to rise?

BKYI
 Stock
  

USD 1.67  0.01  0.60%   

Bio-Key Intl is scheduled to announce its earnings today. While some baby boomers are getting worried about their positions in industrials space, it is entirely reasonable to concentrate on Bio-Key Intl as a possible position for your existing portfolio. What exactly are Bio-Key Intl shareholders getting in September?
Published over a month ago
View all stories for Bio-Key Intl | View All Stories
Bio-Key Intl is UNDERVALUED at 3.01 per share with modest projections ahead.
We provide trade advice to complement the prevailing expert consensus on Bio-Key Intl. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Bio-Key Intl? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Bio-Key Intl this year

Annual and quarterly reports issued by Bio-Key Intl are formal financial statements that are published yearly and quarterly and sent to Bio-Key stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Bio-Key Intl often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How does Bio-Key utilize its cash?

To perform a cash flow analysis of Bio-Key Intl, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bio-Key Intl is receiving and how much cash it distributes out in a given period. The Bio-Key Intl cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Michael DePasquale of 1000 shares of Bio-Key Intl

Legal trades by Bio-Key Intl insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bio-Key insider trading alert for perchase of common stock by Michael DePasquale, Chief Executive Officer, on 16th of September 2022. This event was filed by Bio Key International Inc with SEC on 2022-09-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Bio-Key a risky opportunity?

Let's check the volatility. Bio-Key is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Bio-Key (NASDAQ:BKYI) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Bio-Key Intl stock makes you a part-owner of that company.

Over 3 percent rise for Bio-Key Intl. What does it mean for stockholders?

The coefficient of variation is down to 2972.7 as of today. Bio-Key Intl shows above-average downside volatility for the selected time horizon. We advise investors to inspect Bio-Key Intl further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Bio-Key Intl future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bio-Key Intl's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bio-Key Intl's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Bio-Key Intl Implied Volatility

Bio-Key Intl's implied volatility exposes the market's sentiment of Bio-Key Intl stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Bio-Key Intl's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Bio-Key Intl stock will not fluctuate a lot when Bio-Key Intl's options are near their expiration.

The Current Takeaway on Bio-Key Intl Investment

While some firms under the security & protection services industry are still a bit expensive, Bio-Key Intl may offer a potential longer-term growth to stockholders. In closing, as of the 12th of August 2022, we believe that Bio-Key Intl is currently undervalued with low chance of financial distress in the next two years. Our latest 90 days Buy-Hold-Sell recommendation on the company is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Bio-Key Intl. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com